Pfizer, PhRMA back SOPA amid online protests

With dozens of websites blocked in protest of new anti-piracy legislation, Pfizer ($PFE) and PhRMA are among the intellectual-property champions that are lobbying for, rather than against, the proposed laws. Pfizer says the measures--one approved by the House, another by the Senate--would help prevent drug counterfeiting. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.